Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof

US10160806B2 · kind B2 · utility

Assignee

• Macrogenics, Inc. · US

Inventors

• Ezio Bonvini · Potomac, US
• Leslie S. Johnson · Travilah, US
• Kalpana Shah · Rockville, US
• Ross La Motte-Mohs · Boyds, US
• Paul A. Moore · North Potomac, US
• Scott Koenig · Rockville, US

Key dates

• Filing date: Jun 19, 2015
• Grant date: Dec 25, 2018
• Expiry date: Jun 19, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-I×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”).